Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

• Published in: American Journal of Men's Health 2024-03, Vol.18 (2), p.15579883241234747
• Main Authors: Xiang, Qin, Liu, Yueguang, Xiao, Junwen, Ou, Longhua, Du, Jianhui
• Format: Article
• Language: English
• Subjects: Humans; Lymphocyte Count; Lymphocytes; Male; Medical prognosis; Meta-analysis; Monocytes; Prognosis; Prostate cancer; Prostatic Neoplasms - blood; Prostatic Neoplasms - mortality
• ISSN: 1557-9883; 1557-9891; 1557-9891
• DOI: 10.1177/15579883241234747

The objective of this study is to evaluate the prognostic value of lymphocyte-to-monocyte ratio (LMR) in patients with prostate cancer (PCa) by a method of meta-analysis. China National Knowledge Infrastructure (CNKI), Wanfang Data, PubMed, Web of Science, Cochrane Library, and Embase were searched to collect relevant literature until March 2023. The Newcastle-Ottawa Scale was used to assess the bias risk of the literature included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the prognostic value of LMR in PCa. Stata 15.0 statistical software was used for data analysis. A total of six published articles were included in this meta-analysis, containing 1,104 patients with PCa. The results of the meta-analysis indicated better overall survival (OS; HR = 1.73, 95% CI: 1.73, p = .001) and progression-free survival (PFS; HR = 2.63, 95% CI: 1.58~4.38, p < .001) in patients with PCa with low LMR compared with high LMR. In conclusion, compared with low LMR, PCa patients with high LMR have a better prognosis. LMR is an independent risk factor affecting the long-term prognosis of patients with PCa. The detection of LMR before treatment is of certain significance in judging the clinical prognosis of patients with PCa.